| Ident. | Authors (with country if any) | Title |
|---|
| 000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 000082 |
Maria Gabriela Sanchez [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys |
| 000173 |
Golnasim Riahi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Pershia Samadi [Canada] ; Martin Parent [Canada] ; Thérèse Di Paolo [Canada] | Effect of chronic L-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain |
| 000202 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
| 000216 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease |
| 000256 |
Bazoumana Ouattara [Canada] ; Laurent Gregoire [Canada] ; Marc Morissette [Canada] ; Fabrizio Gasparini [Suisse] ; Ivo Vranesic [Suisse] ; Graeme Bilbe [Suisse] ; Donald R. Johns [Suisse] ; Alex Rajput [Canada] ; Oleh. Hornykiewicz [Autriche] ; Ali H. Rajput [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Therese Di Paolo [Canada] | Metabotropic glutamate receptor type 5 in levodopa-induced motor complications |
| 000271 |
Anne M. Landau [Danemark, Canada] ; M. Mallar Chakravarty [Danemark, Canada] ; Campbell M. Clark [Canada] ; Athanasios P. Zis [Canada] ; Doris J. Doudet [Danemark, Canada] | Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates |
| 000308 |
Marc Morissette [Canada] ; Pershia Samadi [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Nancy Belanger [Canada] ; Thérèse Di Paolo [Canada] | Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys |
| 000316 |
Robert A. Hodgson [États-Unis] ; Paul J. Bedard [Canada] ; Geoffrey B. Varty [États-Unis] ; Tatiana M. Kazdoba [États-Unis] ; Therese Di Paolo [Canada] ; Michael E. Grzelak [États-Unis] ; Annamarie J. Pond [États-Unis] ; Abdallah Hadjtahar [Canada] ; Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; Aurelie Dare [Canada] ; Bernard R. Neustadt [États-Unis] ; Andrew W. Stamford [États-Unis] ; John C. Hunter [États-Unis] | Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders |
| 000361 |
Bazoumana Ouattara [Canada] ; Fabrizio Gasparini [Suisse] ; Marc Morissette [Canada] ; Laurent Gregoire [Canada] ; Pershia Samadi [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Thérèse Di Paolo [Canada] | Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys |
| 000362 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease |
| 000384 |
B. Ouattara [Canada] ; D. Hoyer [Suisse] ; L. Gregoire [Canada] ; M. Morissette [Canada] ; F. Gasparini [Suisse] ; B. Gomez-Mancilla [Suisse] ; T. Di Paolo [Canada] | CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS |
| 000599 |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
| 000697 |
J. Miklossy [Canada] ; D. D. Doudet [Canada] ; C. Schwab [Canada] ; S. Yu [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Role of ICAM-1 in persisting inflammation in parkinson disease and MPTP monkeys |
| 000701 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
| 000708 |
Carl Julien [Canada] ; Line Berthiaume [Canada] ; Abdallah Hadj-Tahar [Canada] ; Ali H. Rajput [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Pierre Julien [Canada] ; Frédéric Calon [Canada] | Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys |
| 000737 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Claude Rouillard [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Daniel Levesque [Canada] | Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys |
| 000747 |
Maryka Quik [États-Unis] ; Neeraja Parameswaran [États-Unis] ; Sarah E. Mccallum [États-Unis] ; Tanuja Bordia [États-Unis] ; SHANSHAN BAO [États-Unis] ; Alison Mccormack [États-Unis] ; Amy Kim [États-Unis] ; Rachel F. Tyndale [Canada] ; J. William Langston [États-Unis] ; Donato A. Di Monte [États-Unis] | Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates |
| 000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000800 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
| 000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
| 000861 |
D. J. Doudet [Canada] ; M. L. Cornfeldt [États-Unis] ; C. R. Honey [Canada] ; A. W. Schweikert [États-Unis] ; R. C. Allen [États-Unis] | PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease |
| 000914 |
Antonio P. Strafella [Canada] ; Tomas Paus [Canada] ; Maria Fraraccio [Canada] ; Alain Dagher [Canada] | Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex |
| 000926 |
Patrick L. Mcgeer [Canada] ; Claudia Schwab [Canada] ; Andre Parent [Canada] ; Doris Doudet [Canada] | Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration |
| 000933 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada] | Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems |
| 000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 000966 |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
| 000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 000A15 |
James E. Holden [États-Unis] ; Salma Jivan [Canada] ; Thomas J. Ruth [Canada] ; Doris J. Doudet [Canada] | In vivo receptor assay with multiple ligand concentrations: An equilibrium approach |
| 000A43 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
| 000B13 |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
| 000B44 |
Y. L. Xue [République populaire de Chine] ; Z. F. Wang [République populaire de Chine] ; D. G. Zhong [République populaire de Chine] ; X. Cui [République populaire de Chine] ; X. J. Li [République populaire de Chine] ; X. J. Ma [République populaire de Chine] ; L. N. Wang [République populaire de Chine] ; K. Zhu [République populaire de Chine] ; A. M. Sun [Canada] | Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys |
| 000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
| 000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
| 000B97 |
Frédéric Calon [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bedard [Canada] | Dopamine-receptor stimulation : biobehavioral and biochemical consequences |
| 000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
| 000C13 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
| 000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
| 000C60 |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
| 000C62 |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
| 000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
| 000C69 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content |
| 000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
| 000D59 |
R. Levy [France] ; L.-N. Hazrati [Canada] ; M.-T. Herrero [France, Espagne] ; M. Vila [France] ; O.-K. Hassani [France] ; M. Mouroux [France] ; M. Ruberg [France] ; H. Asensi [Espagne] ; Yves Agid [France] ; J. Feger [France] ; J. A. Obeso [Espagne] ; A. Parent [Canada] ; E. C. Hirsch [France] | Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states |
| 000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
| 000D85 |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
| 000D94 |
M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J. Blanchet [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression : In situ hybridization histochemical analysis |
| 000E22 |
J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |
| 000E28 |
M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada] | Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys |
| 000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 000E31 |
P. J. Blanchet [Canada] ; R. Grondin [Canada] ; P. J. Bedard [Canada] ; K. Shiosaki [États-Unis] ; D. R. Britton [États-Unis] | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates |
| 000E36 |
R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
| 000E58 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
| 000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
| 000E66 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
| 000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
| 000E83 |
M. Filion [Canada] ; L. Tremblay ; M. Matsumura ; H. Richard | Focalisation dynamique de la convergence informationnelle dans les noyaux gris centraux |
| 000E93 |
M.-C. Asselin [Canada] ; J.-J. Soghomonian ; P.-Y. Côte ; A. Parent | Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys |
| 000F10 |
P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
| 000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
| 000F46 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
| 000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 000F57 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 000F89 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
| 000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 001029 |
M. Filion ; L. Tremblay ; P. J. Bedard | Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001030 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism |
| 001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
| 001040 |
M. Filion ; L. Tremblay | Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001054 |
D. Pare ; R. Curro'Dossi ; M. Steriade | Neuronal basis of the Parkinsonian resting tremor : a hypothesis and its implications for treatment |
| 001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001064 |
C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
| 001081 |
VOON WEE YONG ; M. Guttman ; S. U. Kim ; D. B. Calne ; I. Turnbull ; K. Watabe ; R. W. W. Tomlinson | Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms |
| 001085 |
L. Tremblay ; M. Filion ; P. J. Bedard | Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism |
| 001097 |
C. Harnois ; G. Marcotte ; T. Di Paolo | Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence |
| 001112 |
M. Pisa | Regional specialization of motor functions in the rat striatum: implications for the treatment of parkinsonism |
| 001126 |
P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
| 001129 |
M. Filion ; L. Tremblay ; P. J. Bedard | Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys |
| 001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 001135 |
T. L. Perry ; VOON WEE YONG ; S. Hansen ; K. Jones ; C. Bergeron ; J. G. Foulks ; J. M. Wright | α-Tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 001171 |
T. Di Paolo ; P. Bedard ; M. Daigle ; R. Boucher | Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
